{"id":"ad-2282","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, AD-2282 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.","oneSentence":"AD-2282 is a small molecule that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:26.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06858865","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2025-07-12","conditions":"Primary Hypercholesterolaemia","enrollment":60},{"nctId":"NCT06747936","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282","status":"NOT_YET_RECRUITING","sponsor":"Addpharma Inc.","startDate":"2025-02","conditions":"Primary Hypercholesterolemia","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD-2282","genericName":"AD-2282","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD-2282 is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}